All In Biotech

Free tool

FAERS Monitor: Xenleta

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 211672 or its brand name (Xenleta, Lefamulin Acetate). Reports on generic versions are filed under their own applications.

Reports

17

Serious

3

18% of reports

Hospitalization

1

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea7
  • vomiting4
  • nausea3
  • product use in unapproved indication3
  • abdominal discomfort2
  • palpitations2
  • pneumonia2
  • abdominal pain upper1
  • cold sweat1
  • death1
  • drug ineffective1
  • feeling abnormal1
  • gastrointestinal disorder1
  • headache1
  • hypersensitivity1

Reports by year received

View as table
YearReports
20208
20218
20221

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,142 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
cold sweat170.210.517
palpitations221.15.721
product use in unapproved indicationSignal315.05.427
abdominal discomfort214.84.014
gastrointestinal disorder113.82.13
diarrhoeaSignal713.47.671
vomitingSignal410.54.526
pneumonia27.62.16
hypersensitivity16.71.01
abdominal pain upper16.00.91
feeling abnormal15.20.80
nauseaSignal34.71.76
headache12.00.30
death11.40.20
drug ineffective10.90.10

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.